Patents by Inventor Marco Ciufolini

Marco Ciufolini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS
    Publication number: 20080255141
    Abstract: Novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles of formula (I) that selectively modulate, regulate, and/or inhibit signal transductions mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferation metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
    Type: Application
    Filed: July 18, 2007
    Publication date: October 16, 2008
    Inventors: Marco Ciufolini, Camille Wermuth, Bruno Gielthen, Alain Moussy
  • 2-(3-Aminoaryl)amino-4-aryl-thiazoles for the treatment of diseases
    Patent number: 7423055
    Abstract: The present invention relates to novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: September 9, 2008
    Assignee: AB Science
    Inventors: Marco Ciufolini, Camille Wermuth, Bruno Gielthen, Alain Moussy
  • 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors
    Publication number: 20080039466
    Abstract: The present invention relates to novel compounds selected from 2-(3substitutedaryl)amino-4-aryl-thiazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
    Type: Application
    Filed: January 28, 2005
    Publication date: February 14, 2008
    Inventors: Alain Moussy, Marco Ciufolini, Camille Wermuth, Bruno Giethlen
  • 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors
    Publication number: 20070142390
    Abstract: The present invention relates to novel compounds selected from 2-aminoaryloxazoles of formula I that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
    Type: Application
    Filed: October 22, 2004
    Publication date: June 21, 2007
    Inventors: Alain Moussy, Camille Wermuth, David Grierson, Abdellah Benjahad, Martine Croisy, Marco Ciufolini, Bruno Giethlen
  • 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
    Publication number: 20050239852
    Abstract: Novel compounds selected from 2-(3-aminoaryl) amino-4-aryl-thiazoles of formula (I) that selectively modulate, regulate, and/or inhibit signal transductions mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
    Type: Application
    Filed: July 31, 2003
    Publication date: October 27, 2005
    Applicant: AB Science
    Inventors: Marco Ciufolini, Camille Wermuth, Bruno Gielthen, Alain Moussy
  • 2-(3-Aminoaryl)amino-4-aryl-thiazoles for the treatment of diseases
    Publication number: 20040110810
    Abstract: The present invention relates to novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
    Type: Application
    Filed: August 1, 2003
    Publication date: June 10, 2004
    Applicant: AB Science
    Inventors: Marco Ciufolini, Camille Georges Wermuth, Bruno Gielthen, Alain Moussy
  • Process for preparing camptothecin
    Patent number: 6218540
    Abstract: A process for preparing the anti-cancer drug camptothecin (CPT) and certain derivatives thereof. The process includes the reacting of three base reagents and a five-step process for synthesizing optically pure CPT in high overall yield from inexpensive starting materials.
    Type: Grant
    Filed: May 4, 1999
    Date of Patent: April 17, 2001
    Assignee: BioNumerik Pharmaceuticals, Inc.
    Inventors: Marco Ciufolini, Frank Roschangar